Web Results

dockets.justia.com/docket/louisiana/lawdce/6:2012cv00064/121414

Jan 17, 2012 ... Defendant: Takeda Pharmaceutical Co Ltd, Takeda Pharmaceuticals North America Inc, Takeda Pharmaceuticals L L C, Takeda Pharmaceuticals International Inc, Takeda Global Research & Development Center Inc, Takeda San Diego Inc, Takeda California Inc and Takeda Pharmaceuticals U S A Inc.

dockets.justia.com/docket/new-jersey/njdce/2:2018cv00297/364138

Jan 9, 2018 ... COMBS et al v. TAKEDA PHARMACEUTICAL COMPANY LIMITED et al. Plaintiff: CAREN COMBS and ROBERT COMBS. Defendant: TAKEDA PHARMACEUTICAL COMPANY ... Defendant: TAKEDA PHARMACEUTICALS U.S.A., INC. ... Defendant: TAKEDA DEVELOPMENT CENTER AMERICAS, INC.

www.scotusblog.com/case-files/cases/united-states-ex-rel-noah-nathan-v-takeda-pharmaceuticals-inc-north-america-inc

Mar 31, 2014 ... Jul 12 2013, Brief of respondents Takeda Pharmaceuticals North America, Inc., et al. in opposition filed. Jul 30 2013, Reply of petitioner U. S. ex rel. Noah Nathan filed. Jul 31 2013, DISTRIBUTED for Conference of September 30, 2013. Oct 7 2013, The Solicitor General is invited to file a brief in this case ...

caselaw.findlaw.com/ca-court-of-appeal/1710713.html

Jul 16, 2015 ... Nancy COOPER, Individually and as Successor, etc., Plaintiffs and Appellants, v. TAKEDA PHARMACEUTICALS AMERICA, INC., et al., Defendants and Respondents.

www.lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2015/07/17/california-appeals-court-reinstates-6-5-million-actos-verdict-expert-back-in.aspx

Jul 17, 2015 ... LOS ANGELES — (Mealey's) A California appeals court panel on July 16 reinstated a $6.5 million Actos bladder cancer verdict, finding that the trial court erred in excluding the plaintiffs' causation expert in a post-verdict ruling (Nancy Cooper, et al. v. Takeda Pharmaceuticals America, Inc., et al., No.

www.lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2014/04/08/jury-awards-9b-in-1st-mdl-actos-bladder-cancer-trial-against-takeda-eli-lilly.aspx

Apr 8, 2014 ... Inc., according to Takeda (In Re: Actos [Pioglitazone] Products Liability Litigation, MDL Docket No. 2299, No. 6:11-md-2299, Allen v. Takeda Pharmaceuticals North America Inc., et al., No. 12-64, E.D. La.). According to an April 8 press release issued by Takeda, the nine-member jury in the U.S. District ...

www.law360.com/cases/4def4e02ca42e20f71000002

Parties, docket activity and news coverage of federal case STRECK v. ALLERGAN, INC., ET AL, case number 2:08-cv-05135, from Pennsylvania Eastern Court.

www.ncbi.nlm.nih.gov/pmc/articles/PMC5076775

Sep 25, 2016 ... Unlike other drugs in this class, the PPI dexlansoprazole is formulated as a capsule with a dual delayed-release mechanism [Vakily et al. 2009; Takeda Pharmaceuticals America, Inc., 2016]. According to the dual delayed-release mechanism, dexlansoprazole is first released 1–2 hours after ingestion, ...

www.supremecourt.gov/orders/courtorders/100713zor_5436.pdf

Oct 7, 2013 ... The motion of petitioner to dispense with printing the joint appendix is granted. 12 -1349. U. S., EX REL. NATHAN V. TAKEDA PHARMACEUTICALS, ET AL. 12- 1351. MEDTRONIC, INC. V. STENGEL, RICHARD, ET UX. 12-1497. KELLOGG BROWN & ROOT, ET AL. V. UNITED STATES, EX REL. CARTER.